[A18-53] Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V
|2018-12-03||Executive summary of dossier assessment (German version)||105 kB|
|2018-12-03||Dossier assessment (German version)||663 kB|
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.